National and Regional Market Penetration Rates of Generic's High Dosage Buprenorphine: Its Evolution from 2006 to 2008, Using Reimbursed Drug Database

Objective. To assess the national market penetration rate (PR) of generic high-dosage buprenorphine (HDB) in 2008 and its evolution since their marketing (2006), and making a point for each dosage and at regional level. Methods. Retrospective study over data using national and regional health reimbursement database over three years (2006-2008). Results. In 2008, the generic HDB's national MPR was 31%. The PR for each dosage were 45% for 0.4 mg, 36% for 2 mg and 19% for 8 mg. The (PR) based on Defined Daily Dose (DDD) was 23% in 2008, 15% in 2007 and 4% in 2006. In 2008, at the regional level, disparities were observed in the adjusted penetration rate from 15% in ?le de France to 39% in Champagne Ardennes Lorraine. Conclusion. The national PR of generic HDB has increased. There are differences in MPR in terms of dosage and area. However, this PR is still low (in 2008, 82% of the delivered drugs are generics).